Metformina + Sitagliptina Bluepharma (Metformin Hydrochloride, Sitagliptin)

Metformin Hydrochloride primarily reduces hepatic glucose production and increases peripheral insulin sensitivity, which lowers circulating glucose levels. Sitagliptin, the second component, blocks the DPP‑4 enzyme, prolonging the action of incretin hormones that stimulate insulin release and suppress glucagon, together achieving tighter glucose regulation.

The dosage of Metformina + Sitagliptina is determined by the prescribing healthcare professional based on individual patient factors such as renal function, age, and glycemic targets. Physicians tailor the strength and frequency to achieve optimal blood‑sugar control while minimizing adverse effects.

Safety in pregnancy and lactation has not been fully established for this combination. Generally, metformin may be continued if benefits outweigh risks, whereas sitagliptin is usually avoided. Women who are pregnant, planning pregnancy, or breastfeeding should discuss alternatives with their healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Compared with metformin alone, the addition of sitagliptin offers greater reduction in HbA1c and better post‑prandial glucose control without a substantial increase in hypoglycemia risk. Relative to other DPP‑4 inhibitors, sitagliptin has a well‑characterised safety profile and once‑daily dosing, making the combination convenient for many patients.

Store the tablets at room temperature, ideally below 25 °C, in the original blister pack or container. Protect them from excess moisture, direct sunlight and heat. Do not refrigerate or freeze the product, and keep it out of reach of children.

Metformina + Sitagliptina is taken orally, usually with a glass of water. It can be taken with or without food, but consistent timing with meals may help reduce gastrointestinal discomfort. Patients should follow the dosing schedule prescribed by their clinician.

The most critical adverse events to monitor are lactic acidosis (rare but potentially fatal), acute pancreatitis, and severe hypersensitivity reactions such as anaphylaxis or angioedema. Prompt medical attention is required if patients experience unexplained abdominal pain, rapid breathing, or signs of an allergic reaction.

The combination is contraindicated in patients with severe renal impairment (eGFR < 30 mL/min/1.73 m²), significant hepatic disease, or in those with a history of lactic acidosis. It should also be avoided in individuals with known hypersensitivity to metformin, sitagliptin, or any excipients in the formulation.